article
Recent News
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.Read Article
Dr. John Cush
Tweet
Artiva has stopped development of its AlloNK (allogeneic NK cell therapy) after 2 reported deaths in their phase II RCT in #RA and other autoimmune conditions. Artiva has suspended its phase III trial with AlloNK. https://t.co/mLR6xciRfB https://t.co/mv2m8rhst6
Dr. John Cush
Tweet
Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th!
Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more.
Visit https://t.co/ofGKCCNQnE for the latest coverage.
#ACR26 #Rheumatology https://t.co/5p5UxMLu51
Dr. John Cush
Tweet
Rituximab or Azathioprine for EGPA Maintenance?
A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone.
https://t.co/UrHqPBVibn https://t.co/ZumTjOcrEa
Dr. John Cush
Tweet
Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top?
The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage.
https://t.co/J1EQHGzR5O https://t.co/w3rQ3AbrYt
article
Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.
article
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Dr. John Cush
Tweet
Medicaid adults w/ new low back pain Rx w/ higher-dose opioids have a 2.5 fold risk of later opioid use disorder or overdose. Retro study of ~400K opioid naive LBP pts https://t.co/9CTqaQ17vz https://t.co/hCY9KwCqLx
Dr. John Cush
Tweet
CLARITY-1 & CLARITY-2 Phase 3 Trials show Brepocitinib effective in Non-Infectious Uveitis. 371 pts Rx w. brepocitinib 45 mg or placebo x48wks w/ 2 wks of Pred taper. Time to Rx failure greater w/ BREP (48 vs 12 wks PBO; p<0.0001)https://t.co/EBaWe7TJbt https://t.co/UVg188eEHZ
Dr. John Cush
Tweet
Beverages & relative risk of hyperuricemia (HUA) & gout. Metanalysis of 52 studies shows alcohol has signif high risk of gout (OR 1.8) & HUA (OR 1.5); & sugar-sweetened beverages (SSBs) incr gout (1.37) & HUA (1.48); as well as tea for HUA among female (OR = 1.29). Coffee https://t.co/nq1fKvOlgv
Dr. John Cush
Tweet
High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. (CDC https://t.co/wnPdEueb4N
Dr. John Cush
Tweet
Rheum Survey on SCLE> In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE). CLICK HERE>> https://t.co/LdnYIw0Qw3 https://t.co/qWUqwFpLta
Dr. John Cush
Tweet
Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/KtH0AIatdq
Dr. John Cush
Tweet
Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk?
Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup:
- JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt
Dr. John Cush
Tweet
TENS does NOT work in knee OA (KOA). Sham controlled RCT of 96 KOA pts (all Rx w/ exercise) randomized to TENS or sham show no betw group difference in KOOS score at 1 mo, nor did they achieve the minimal clinically important difference. https://t.co/1xPtNn7MM0 https://t.co/GLCfzWP39D
Dr. John Cush
Tweet
Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. https://t.co/U28aBsQpJ8 https://t.co/g9Ak2MCJEN
Dr. John Cush
Tweet
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c
Dr. John Cush
Tweet
van Vollenhoven’s Treatment Advances in Lupus
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
https://t.co/5oCf60XmuJ https://t.co/8TGC1Y4Cqp
Dr. John Cush
Tweet
Comorbidity management is subpar in Rheum. Surveys of 2213 inflamm rheum Dz pts & 140 rheumatologists. Rheums think theyre OK (71-92%) screening (HTN, OP, vaccines, CA), but pts say NOT (12=33%).Rheums agree they have no structured comorbidity screening in place (time 91%, https://t.co/mqcptziRdw
Video
Podcasts
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Double Trouble (10.23.2026)-
Troubles with ‘Gut Feelings’
-
Don’t Hold the JAK (10.9.2026)
Therapeutic Updates
Clinical dilemmas in axSpA and PsA
Sponsored by UCB
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post
PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post
Obesity – Inflammation – PsA
Sponsored by Lilly Medical Affairs
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
